Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) Short Interest Update

Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) was the recipient of a significant increase in short interest in November. As of November 15th, there was short interest totalling 4,480,000 shares, an increase of 28.0% from the October 31st total of 3,500,000 shares. Approximately 3.5% of the shares of the stock are short sold. Based on an average daily volume of 1,100,000 shares, the short-interest ratio is presently 4.1 days.

Insider Activity

In related news, SVP Jason B. Daly sold 43,657 shares of the firm’s stock in a transaction on Friday, November 15th. The shares were sold at an average price of $8.61, for a total value of $375,886.77. Following the completion of the transaction, the senior vice president now directly owns 13,665 shares of the company’s stock, valued at approximately $117,655.65. This trade represents a 76.16 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Company insiders own 26.56% of the company’s stock.

Institutional Trading of Amneal Pharmaceuticals

Several hedge funds have recently modified their holdings of AMRX. Vanguard Group Inc. boosted its stake in Amneal Pharmaceuticals by 0.6% in the first quarter. Vanguard Group Inc. now owns 13,728,233 shares of the company’s stock valued at $83,193,000 after acquiring an additional 85,846 shares in the last quarter. Bank of New York Mellon Corp increased its holdings in Amneal Pharmaceuticals by 20.7% in the 2nd quarter. Bank of New York Mellon Corp now owns 751,403 shares of the company’s stock worth $4,771,000 after buying an additional 128,772 shares during the period. CANADA LIFE ASSURANCE Co raised its position in Amneal Pharmaceuticals by 417.8% during the 1st quarter. CANADA LIFE ASSURANCE Co now owns 36,106 shares of the company’s stock worth $218,000 after buying an additional 29,133 shares during the last quarter. Acadian Asset Management LLC lifted its stake in Amneal Pharmaceuticals by 701.8% during the 2nd quarter. Acadian Asset Management LLC now owns 811,853 shares of the company’s stock valued at $5,148,000 after acquiring an additional 710,598 shares during the period. Finally, Jackson Creek Investment Advisors LLC purchased a new stake in shares of Amneal Pharmaceuticals in the 2nd quarter valued at $1,027,000. 31.82% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of equities analysts have commented on the stock. Truist Financial lifted their price objective on shares of Amneal Pharmaceuticals from $10.00 to $12.00 and gave the stock a “buy” rating in a research note on Wednesday, October 2nd. Barclays lifted their price target on Amneal Pharmaceuticals from $8.00 to $10.00 and gave the stock an “overweight” rating in a research report on Tuesday, August 13th. Piper Sandler upped their price objective on Amneal Pharmaceuticals from $9.00 to $11.00 and gave the company an “overweight” rating in a research report on Monday, November 11th. StockNews.com upgraded Amneal Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Monday, November 11th. Finally, JPMorgan Chase & Co. raised shares of Amneal Pharmaceuticals from an “underweight” rating to a “neutral” rating and set a $9.00 price objective for the company in a research note on Friday, September 6th. One equities research analyst has rated the stock with a hold rating, four have given a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Buy” and a consensus price target of $10.00.

Amneal Pharmaceuticals Trading Down 1.0 %

Shares of NASDAQ:AMRX opened at $8.27 on Monday. The company has a market capitalization of $2.56 billion, a PE ratio of -12.16 and a beta of 1.17. Amneal Pharmaceuticals has a 12-month low of $4.17 and a 12-month high of $9.48. The business’s fifty day simple moving average is $8.52 and its 200-day simple moving average is $7.79.

Amneal Pharmaceuticals Company Profile

Amneal Pharmaceuticals, Inc, together with its subsidiaries, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment offers immediate and extended release oral solid, powder, liquid, sterile injectable, nasal spray, inhalation and respiratory, biosimilar, ophthalmic, film, transdermal patch, and topical products.